1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

‘Imminent’ Generic Approvals Expected To Help US FDA Meet On-Time Review Metric Retroactively

 
• By Derrick Gingery

ANDA action rate dipped below the 90% mandate in second fiscal quarter, another illustration of the effect the pandemic and other issues have on US FDA’s generic drug assessment system.

Generic drug pills
The falling on-time action rate for generic drug applications could be a concern for sponsors. • Source: Alamy

The US Food and Drug Administration missed its on-time generic drug application action commitment during the second fiscal quarter, but the agency expects to be able to use a relatively new accounting technique to get the number officially above water once a few pending applications are adjudicated.

The on-time action rate for original applications in the GDUFA program slipped again during the January-March 2021 period to 89%,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

Gene Therapy Sponsors Seek More US FDA ‘Platform’ Guidance, Offer Master File Idea

 
• By Michael McCaughan

One clear message from a US FDA listening session on leveraging knowledge across cell and gene therapy products is sponsors want more guidance on how the FDA’s new platform therapy pathway will function.

EMA Slashes Average Clock-Stop Extensions By 18% To Speed Up Drug Reviews

 
• By Vibha Sharma

The European Medicines Agency says it is speeding up its review of drug marketing applications through initiatives that restrict requests from companies for additional response time and minimize unnecessary questions from the assessors.

First Cohort Shows Many Routes To US FDA’s Commissioner’s National Priority Voucher

 
• By Sarah Karlin-Smith

Experts raised concerns about the pilot program's larger than expected size and the lack of transparency about the reasons the cohort deserved vouchers over a pool that the FDA said included hundreds of candidates.

US FDA Drug, Biologics Centers Lost Nearly 1,000 Employees In FY 2025 Fourth Quarter

 
• By Derrick Gingery

The hiring and departure data provide more evidence of the extent of the Trump Administration’s efforts to shrink the FDA workforce through cuts and voluntary departures.

More from Pathways & Standards

First Cohort Shows Many Routes To US FDA’s Commissioner’s National Priority Voucher

 
• By Sarah Karlin-Smith

Experts raised concerns about the pilot program's larger than expected size and the lack of transparency about the reasons the cohort deserved vouchers over a pool that the FDA said included hundreds of candidates.

US FDA Drug, Biologics Centers Lost Nearly 1,000 Employees In FY 2025 Fourth Quarter

 
• By Derrick Gingery

The hiring and departure data provide more evidence of the extent of the Trump Administration’s efforts to shrink the FDA workforce through cuts and voluntary departures.

EMD Serono IVF Candidate Among First US FDA Priority Voucher Recipients As Part Of MFN Deal

 
• By Cathy Kelly

A combination of two individual IVF treatments, Pergoveris has the potential to be a lower cost option in the US, one of the qualifications the FDA wants in a National Commissioner's Priority Voucher candidate.